Get the Stockscreener App
32.57
3.38%
-1.14
After Hours:
32.50
-0.07
-0.21%
Viking Therapeutics Inc stock is traded at $32.57, with a volume of 3.75M.
It is down -3.38% in the last 24 hours and up +22.91% over the past month.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$33.71
Open:
$33.14
24h Volume:
3.75M
Relative Volume:
1.04
Market Cap:
$3.66B
Revenue:
-
Net Income/Loss:
$-99.15M
P/E Ratio:
-35.02
EPS:
-0.93
Net Cash Flow:
$-74.25M
1W Performance:
-2.78%
1M Performance:
+22.91%
6M Performance:
-0.55%
1Y Performance:
-42.86%
1-Day Range:
$32.30
$34.01
1-Week Range:
$32.02
$35.40
52-Week Range:
$18.92
$81.73
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
32.57 | 3.79B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Goldman | Neutral |
| Feb-13-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-07-25 | Initiated | Citigroup | Neutral |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Nov-22-24 | Initiated | B. Riley Securities | Buy |
| Nov-04-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-24 | Initiated | JP Morgan | Overweight |
| Jun-27-24 | Initiated | Morgan Stanley | Overweight |
| May-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-26-24 | Reiterated | Oppenheimer | Outperform |
| Mar-07-24 | Initiated | Jefferies | Buy |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| May-31-23 | Resumed | ROTH MKM | Buy |
| Mar-28-23 | Reiterated | Maxim Group | Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| May-01-20 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-25-19 | Initiated | Stifel | Buy |
| Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-14-19 | Reiterated | Maxim Group | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-18-18 | Reiterated | Maxim Group | Buy |
| Sep-18-18 | Reiterated | Raymond James | Outperform |
| Jul-20-18 | Initiated | SunTrust | Buy |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-01-18 | Reiterated | Laidlaw | Buy |
| May-31-18 | Reiterated | Maxim Group | Buy |
| Mar-26-18 | Resumed | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | Maxim Group | Buy |
| Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
Viking Bets Big On Obesity And NASH With Dual-Agonist Pipeline - Finimize
Viking Therapeutics, Inc. (VKTX) Nears Obesity Drug Breakthrough with Phase 3 VK2735 Trial - MSN
Is it the right time to buy Viking Therapeutics Inc. stockFree Stock Recommendation For Fast Growth - jammulinksnews.com
Axsome Therapeutics and Viking Therapeutics: Biotech Stocks to WatchNews and Statistics - IndexBox
Why Viking Therapeutics Inc. stock attracts strong analyst attentionEarly Breakout Entry Point Notifications Sent - metal.it
Sentiment Turns Positive on Viking Therapeutics Inc. — Reversal AheadMarket Entry and Exit Point Tips From Traders - metal.it
What is the dividend policy of Viking Therapeutics Inc. stockBeginner Investor Insights That Work - jammulinksnews.com
Better Growth Buy: Eli Lilly vs. Viking Therapeutics - MSN
How does Viking Therapeutics Inc. compare to its industry peersDynamic investment growth - jammulinksnews.com
Raymond James Financial Issues Pessimistic Forecast for Viking Therapeutics (NASDAQ:VKTX) Stock Price - MarketBeat
Why is Viking Therapeutics Inc. stock attracting strong analyst attentionTriple returns potential - jammulinksnews.com
What catalysts could drive Viking Therapeutics Inc. stock higher in 2025Rapid market gains - jammulinksnews.com
Is Viking Therapeutics Inc. stock overvalued or undervaluedAI Powered Tips For 2025 - jammulinksnews.com
Viking Therapeutics’ Earnings Call: Clinical Advances Amid Financial Challenges - TipRanks
What are the technical indicators suggesting about Viking Therapeutics Inc.Maximize your returns with expert insights - jammulinksnews.com
What institutional investors are buying Viking Therapeutics Inc. stockBuild wealth with reliable stock picks - jammulinksnews.com
What are analysts’ price targets for Viking Therapeutics Inc. in the next 12 monthsRecord-setting profit potential - jammulinksnews.com
When is Viking Therapeutics Inc. stock expected to show significant growthTremendous growth potential - jammulinksnews.com
Viking Therapeutics Stock Soars Amid Clinical Progress - TipRanks
Viking Therapeutics EPS miss sends shares down 7% - MSN
Viking Therapeutics Inc. Stock Analysis and ForecastUnmatched market gains - PrintWeekIndia
Behind the Scenes of Viking Therapeutics's Latest Options Trends - Benzinga
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales - MSN
Is Viking Therapeutics Inc. a good long term investmentPhenomenal investment performance - PrintWeekIndia
H.C. Wainwright Reiterates a Buy Rating on Viking Therapeutics (VKTX), Sets a $102 PT - MSN
Viking Therapeutics Q2: Confidently Continuing The Recovery (NASDAQ:VKTX) - Seeking Alpha
Analysts Are Bullish on These Healthcare Stocks: Thermo Fisher (TMO), Viking Therapeutics (VKTX) - The Globe and Mail
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q2 2025 Earnings Call Transcript - Insider Monkey
Truist Financial Sticks to Their Buy Rating for Viking Therapeutics (VKTX) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Viking Therapeutics (VKTX), Opus Genetics (IRD) - The Globe and Mail
Viking Therapeutics Receives Buy Rating Amid Promising Clinical Developments and Strategic Initiatives - TipRanks
What drives Viking Therapeutics Inc. stock priceAccelerated wealth expansion - PrintWeekIndia
Viking Therapeutics stock maintains Buy rating at Stifel on obesity drug potential - Investing.com
Viking Therapeutics Surges to 433rd in Trading Volume as Strategic Partnership and Clinical Success Fuel Stock Rally - AInvest
Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity - insights.citeline.com
Viking Therapeutics (VKTX) Stock Rating Maintained by Raymond James | VKTX Stock News - GuruFocus
Viking Therapeutics Q2 Earnings Miss Estimates, R&D Expenses Rise - AInvest
Viking Therapeutics stock rating reiterated by Cantor Fitzgerald at $104 - Investing.com Canada
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory - Insider Monkey
Viking Therapeutics outlines Phase III VANQUISH trial enrollment of 5,600 patients while advancing oral obesity program - MSN
H.C. Wainwright reiterates Buy rating on Viking Therapeutic stock at $102 - Investing.com Nigeria
Viking Therapeutics Inc Stock (VKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):